JP2024518335A - ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用 - Google Patents

ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用 Download PDF

Info

Publication number
JP2024518335A
JP2024518335A JP2023566420A JP2023566420A JP2024518335A JP 2024518335 A JP2024518335 A JP 2024518335A JP 2023566420 A JP2023566420 A JP 2023566420A JP 2023566420 A JP2023566420 A JP 2023566420A JP 2024518335 A JP2024518335 A JP 2024518335A
Authority
JP
Japan
Prior art keywords
seq
antibody
cov
antigen
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518335A5 (https=
Inventor
ムーケ，ヒューゴ
プランシェ，シリル
シュワルツ，オリヴィエ
フェルナンデス，イグナシオ
ブリュエル，ティモシー
モンタグテッリ，ザビエル
ブーイ，エルヴェ
デ メロ，ギリェルメ ディアス
レイ，フェリックス
Original Assignee
アンスティチュ パスツール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンスティチュ パスツール filed Critical アンスティチュ パスツール
Publication of JP2024518335A publication Critical patent/JP2024518335A/ja
Publication of JP2024518335A5 publication Critical patent/JP2024518335A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023566420A 2021-04-26 2022-04-01 ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用 Pending JP2024518335A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IB2021000314 2021-04-26
IBPCT/IB2021/000314 2021-04-26
EP21306908 2021-12-22
EP21306908.1 2021-12-22
IB2022000108 2022-02-25
IBPCT/IB2022/000108 2022-02-25
PCT/EP2022/058777 WO2022228827A1 (en) 2021-04-26 2022-04-01 Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof

Publications (2)

Publication Number Publication Date
JP2024518335A true JP2024518335A (ja) 2024-05-01
JP2024518335A5 JP2024518335A5 (https=) 2025-03-24

Family

ID=81328034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566420A Pending JP2024518335A (ja) 2021-04-26 2022-04-01 ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用

Country Status (5)

Country Link
US (1) US20240336672A1 (https=)
EP (1) EP4330278A1 (https=)
JP (1) JP2024518335A (https=)
KR (1) KR20240006575A (https=)
WO (1) WO2022228827A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024061759A1 (en) * 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
CN120129695A (zh) * 2022-12-20 2025-06-10 北京昌平实验室 新型冠状病毒xbb.1.5及相关变异株广谱中和抗体及应用
CN120035605A (zh) * 2022-12-20 2025-05-23 北京昌平实验室 新型冠状病毒奥密克戎突变株广谱中和抗体及应用
EP4442276A1 (en) 2023-04-07 2024-10-09 Institut Pasteur Combined antibodies against sarbecoviruses and uses thereof
WO2025140539A1 (en) * 2023-12-29 2025-07-03 The University Of Hong Kong Ultrapotent broardly neutralizing antibodies against sars-cov-2 variants and methods of use thereof
WO2025153707A1 (en) 2024-01-19 2025-07-24 Spikimm Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof
WO2025153835A1 (en) * 2024-01-19 2025-07-24 Spikimm Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111690059A (zh) * 2020-06-19 2020-09-22 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的单克隆抗体1D7
CN111909260A (zh) * 2020-08-19 2020-11-10 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN111909263A (zh) * 2020-08-19 2020-11-10 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
EP2755986A4 (en) 2011-09-12 2015-05-20 Moderna Therapeutics Inc MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR
US9950065B2 (en) 2013-09-26 2018-04-24 Biontech Rna Pharmaceuticals Gmbh Particles comprising a shell with RNA
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
US10626400B2 (en) 2014-07-04 2020-04-21 Biontech Ag Stabilised formulations of RNA
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
SI3445850T1 (sl) 2016-04-22 2021-12-31 BioNTech SE Postopki za zagotavljanje enoverižne RNA
WO2018010815A1 (en) 2016-07-15 2018-01-18 Biontech Rna Pharmaceuticals Gmbh Formulation for administration of rna
KR20200109310A (ko) 2018-01-11 2020-09-22 비온테크 알엔에이 파마슈티컬스 게엠베하 Rna의 투여를 위한 제형
KR20200143391A (ko) 2018-03-15 2020-12-23 비온테크 알엔에이 파마슈티컬스 게엠베하 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용
WO2021001023A1 (en) 2019-07-02 2021-01-07 Biontech Rna Pharmaceuticals Gmbh Rna formulations suitable for therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CN111690059A (zh) * 2020-06-19 2020-09-22 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的单克隆抗体1D7
CN111909260A (zh) * 2020-08-19 2020-11-10 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN111909263A (zh) * 2020-08-19 2020-11-10 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用

Also Published As

Publication number Publication date
WO2022228827A1 (en) 2022-11-03
US20240336672A1 (en) 2024-10-10
EP4330278A1 (en) 2024-03-06
KR20240006575A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
JP2024518335A (ja) ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用
ES2789348T3 (es) Anticuerpos neutralizantes para GP120 y sus usos
KR101671452B1 (ko) 항ｒｓｖ ｇ 단백질 항체
JP6483337B2 (ja) デングウイルス血清型１のｅタンパク質に対して特異性を有するヒトモノクローナル抗体およびその使用
CN110678196B (zh) 抗hekr-k包膜抗体及其用途
JP2023534923A (ja) ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子
JP2023534922A (ja) ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子
US20230357364A1 (en) Covid-19 antibodies and uses thereof
CN114174331B (zh) 结合人类偏肺病毒融合蛋白的抗体及其用途
WO2021228904A1 (en) Neutralizing antibodies binding to the spike protein of sars-cov-2 suitable for use in the treatment of covid-19, compositions comprising the same and uses thereof
CA2995109A1 (en) Human antibodies against rabies and uses thereof
US10611827B2 (en) Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins
US20240101645A1 (en) Monoclonal antibodies against coronaviruses and uses thereof
US20180057581A1 (en) Antibodies targeting m-csf
CN107922939A (zh) 中和全部种类埃博拉病毒的感染性的单克隆抗体
EP4442276A1 (en) Combined antibodies against sarbecoviruses and uses thereof
US10435463B2 (en) Hepatitis C virus specific antibody
CN117836322A (zh) 针对SARS-CoV-2的人中和单克隆抗体及其用途
US12281155B1 (en) Broadly SARS-CoV-2 neutralizing monoclonal antibodies and uses thereof
CN116041492B (zh) 一种抗rbd抗体及其应用
WO2025140539A1 (en) Ultrapotent broardly neutralizing antibodies against sars-cov-2 variants and methods of use thereof
WO2025153835A1 (en) Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof
WO2023199943A1 (ja) コロナウイルス感染症を処置することに用いられる抗体
WO2025153707A1 (en) Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof
AU2021408144A1 (en) Sars-cov-2 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224